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A B S T R A C T
Milk protein derived peptides have numerous well-documented bioactive properties. The conventional approach
for the generation, identification and validation of bioactive peptides (BAPs) has involved (i) protein hydrolysis,
(ii) bioactivity screening and (iii) validation in vivo. The low potency (in comparison to conventional drugs),
susceptibility to breakdown during gastrointestinal transit and low intestinal permeability are key challenges in
the development of highly bioactive food protein hydrolysates/peptides. However, the generation of potent and
effective health enhancing hydrolysates/peptides can benefit from a range of in silico techniques including the
application of structure bioactivity relationship modelling (e.g., quantitative structure activity relationship
(QSAR) modelling), molecular docking and design of experiments (DOE) approaches to optimise BAP production
and identification. Some examples of how these approaches have been employed in BAP discovery and gen-
eration will be outlined.
1. Introduction
The food proteome contains peptide sequences, known as bioactive
peptides (BAPs), which have the ability to beneficially modulate a
range of biomarkers associated with health enhancement (Arroume
et al., 2016; Brandelli, Daroit, & Corrêa, 2015; Hernández-Ledesma,
García-Nebot, Fernández-Tomé, Amigo, & Recio, 2014; Liu &
Udenigwe, 2019; Mohanty, Mohapatra, Misra, & Sahu, 2016;
Nongonierma & FitzGerald, 2015; Nongonierma, O’Keeffe, &
FitzGerald, 2016; Sánchez & Vázquez, 2017; Siltari, Vapaatalo, &
Korpela, 2019; Udenigwe & Aluko, 2012). These BAPs have been as-
sociated with beneficial effects on the gastrointestinal, cardiovascular,
immune and nervous systems (Aluko, 2015; Bhat, Kumar, & Bhat, 2015;
Chalamaiah, Yu, & Wu, 2018; Cicero, Fogacci, & Colletti, 2017;
Fernández-Tomé et al., 2016; Giromini, Cheli, Rebucci, & Baldi, 2019;
Kaur, 2014; Kiewiet, Faas, & de Vos, 2018; Liu & Udenigwe, 2019;
Reyes-Díaz et al., 2018; Santiago-López, Hernández-Mendoza, Vallejo-
Cordoba, Mata-Haro, & González-Córdova, 2016; Sibel Akalın, 2014;
Wu, Liao, & Udenigwe, 2017). BAPs associated with opioid, mineral
binding, anti-microbial, anti-inflammatory, anti-diabetic and anti-
cancer activities following in vitro/ex vivo assessments have also been
reported (Chalamaiah et al., 2018; Meisel et al., 2003; Nongonierma &
FitzGerald, 2012; Nongonierma, O’Keeffe, et al., 2016). Furthermore, in
vivo studies have, to date, mainly focused on BAPs having anti-cario-
genic, anti-hypertensive and anti-diabetic properties (Aluko, 2015;
Muhammad Ali, Kimia Anaraki, Maryam, & Dérick, 2016; Nongonierma
& FitzGerald, 2015; Nongonierma, O’Keeffe, et al., 2016). The interest
in BAPs arises from consumer perception, awareness and demand that
food components derived from sustainable natural sources have the
ability to contribute to both disease prevention and management along
with health enhancement (Tu, Cheng, Lu, & Du, 2018). This is parti-
cularly the case for conditions associated with non-communicable
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diseases such as type 2 diabetes, hypertension and obesity (Aluko,
2015; O'Neill & O'Driscoll, 2015). Food-derived peptides are thus,
considered as potential functional food ingredients for incorporation
into health-promoting diets targeted at the prevention and management
of these chronic diseases.
Milk proteins from various sources, e.g., bovine, buffalo, camel,
goat, sheep, mare, yak and donkey have been studied with respect to
their potential to yield BAPs having different properties (Zenezini
Chiozzi et al., 2016) (El-Salam & El-Shibiny, 2013). However, to date,
bovine milk proteins appear to be the most frequently studied as
sources of BAPs (Nongonierma et al., 2016). Significant differences in
the primary sequences of the individual milk proteins from different
animal species can influence the physicochemical, techno-functional as
well as biological properties of the peptides released therefrom.
Fatchiyah, Hardiyanti, and Widodo (2015), for example, demonstrated
these differences when comparing bovine and caprine milks. Further-
more, genetic polymorphism in the milk proteins within the same an-
imal breed can also influence the type of BAPs contained within their
primary sequences. For instance, bovine β-casein has been reported to
display at least 15 different genetic variants including β-casein A1-3, B-
G, H1-2, I-L (Bruno et al., 2017). A number of studies have reported on
the impact of genetic polymorphism on the bioactive properties of milk
proteins from different sources (Asledottir et al., 2017; Bruno et al.,
2017; Darwish, El Nady, Ali, & Abdelsalam, 2018; Petrat-Melin, Le,
Møller, Larsen, & Young, 2017; Ryskaliyeva et al., 2019; Haq, Kapila,
Sharma, Saliganti, & Kapila, 2014).
The conventional approach for BAP discovery involves several steps,
as shown in Fig. 1. These include selection of the substrate and enzyme,
in vitro bioactivity screening, enrichment/fractionation of active frac-
tions, identification of peptide sequences followed by validation in in
vivo studies. This approach requires significant effort as it is time con-
suming and inefficient since it is non-targeted and is not always
successful. Therefore, the use of a more targeted approach employing
bioinformatics, also known as in silico analysis, has become popular as a
powerful tool for BAP discovery due to its more rapid rate of results
acquisition and recovery, less chemical-reagent use/consumption and
resultant cost effectiveness (Dziuba & Dziuba, 2010; Nongonierma,
O’Keeffe, et al., 2016; Liu, Cheng, & Wu, 2019). This approach refers to
the exploitation of computational methods to manage, curate and in-
terpret information from biological systems, in this case, for the more
efficient discovery of food protein-derived BAPs (Li-Chan, 2015).
Various in silico methodologies are currently being employed to aid
the discovery of milk protein derived BAPs (Dziuba & Dziuba, 2010; Liu
et al., 2019; Nongonierma & FitzGerald, 2017; Nongonierma, O'Keeffe
&amp; FitzGerald). These include in silico approaches for:
(i) selection of the most appropriate protein substrate for generation
of BAPs using different criteria such as frequency of BAP occur-
rence, frequency of BAPs potentially released and BAP potency
scores for different food protein substrates. These have recently
been reviewed and studied for various food protein substrates
(Han, Maycock, Murray, & Boesch, 2019; Ibrahim, Bester, Neitz, &
Gaspar, 2019; Lin et al., 2018, b, 2018, a, Nongonierma &
FitzGerald, 2014, 2018, b)
(ii) determination of the mechanism of action of BAPs by elucidating
structure–activity relationships between BAPs and various biolo-
gical activities, e.g., using quantitative structure–activity re-
lationship (QSAR) modelling (Nongonierma et al., 2018)
(iii) virtual screening of large numbers of peptide sequences using
molecular docking to determine specific interactions between
peptides and specific enzyme active sites and/or receptors (Li-
Chan, 2015)
(iv) optimisation of BAP release during enzymatic hydrolysis and fer-
mentation using design of experiments (DOE) in combination with
Fig. 1. Diagrammatic representation of conventional and in silico approaches for food-protein derived bioactive peptide (BAP) discovery. QSAR: quantitative
structure activity relationship; DOE: design of experiment; RSM: response surface methodology (adapted from Nongonierma et al., 2017).
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response surface methodology (RSM) (Nongonierma & FitzGerald,
2016b, 2018)
This review focuses on the application of in silico approaches to aid
the selection of appropriate substrate(s) and enzyme(s) for BAP gen-
eration. Furthermore, the application of molecular docking, QSAR and
DOE for BAP discovery and optimised release from food protein sub-
strates is outlined in this review.
2. BAP release from food proteins by enzymatic hydrolysis:
conventional and in silico approaches
BAPs are encrypted in the precursor protein sequences in an inactive
form and can be released using various approaches including (i) in vitro
enzymatic hydrolysis, (ii) microbial fermentation, (iii) physical/che-
mical processes (e.g., ultrasonic, microwave and acid or alkaline
treatments) and (iv) in vivo gastrointestinal digestion (Nongonierma,
O’Keeffe, et al., 2016). Furthermore, the possibility exists for BAP re-
lease using combinations of the above enzymatic approaches, e.g., as
may occur following the ingestion of fermented foods (BAPs may also
be released during the action of enzymatic activities associated with the
gut microbiome). However, to date in vitro enzymatic hydrolysis is the
most studied approach for BAP release.
Proteins from edible animal, plant and marine sources have been
the main substrates for BAP generation. During in vitro enzymatic hy-
drolysis, proteins from these sources are hydrolysed using commercially
available food-grade enzyme preparations. These enzyme preparations
originate from mammalian, plant and microbial sources and have
specific characteristics, e.g., main hydrolytic activity and optimum pH
and temperature working ranges (for more details see: Gurumallesh,
Alagu, Ramakrishnan, and Muthusamy (2019); Nongonierma and
FitzGerald (2018); Toldrá, Reig, Aristoy, and Mora (2018)). However,
these enzyme preparations may display significant batch-to-batch
variability in their enzymatic activity (Merz et al., 2016). In addition,
while containing a dominant hydrolytic activity, in many cases they
may also contain different side-activities. This is exemplified by the
Bacillus-derived enzyme preparation Alcalase® which has subtilisin as
its main activity but also contains a glutamyl endopeptidase side ac-
tivity (Spellman, O’Cuinn, & FitzGerald, 2009). These factors may lead
to variability in the peptides released from specific food protein sub-
strates (Nongonierma & FitzGerald, 2018). Another limitation of the
conventional approach to BAP generation is that it is non-targeted and
essentially involves an empirical strategy for BAP generation, as out-
lined in Fig. 1. Given the above limitations, in silico approaches are
being increasingly employed to select specific protein substrates and
hydrolytic enzymes for the targeted generation of BAPs (Fig. 1).
In this regard, it is possible to predict the BAPs that may be released
from specific food proteins using selected proteolytic/peptidolytic en-
zymes using information available in online databases. The primary
sequences of the milk protein molecules are available in, e.g., UniProt
and NCBI. Furthermore, the sequences of different BAPs reported to be
present in different milk proteins are publically available in databases
such as BIOPEP-UWM (University of Warmia and Mazury), PepBank,
PeptideLocator and PeptideDB. In addition, substrate specific BAP da-
tabases such as the Milk Bioactive Peptide Database (MBPDB) (Nielsen,
Beverly, Qu, & Dallas, 2017) and bioactivity specific databases such as
the Collection of Anti-microbial Peptides (CAMP) and the Antimicrobial
Peptide Database (APD) are also publically available (more detailed
information on bioactive peptide databases as well as bio-tools asso-
ciated with peptide sequence processing have been reviewed by Iwa-
niak, Darewicz, Mogut, and Minkiewicz (2019)). Specific enzyme cutter
tools, e.g., PeptideCutter and ‘Enzyme(s) action’ in the BIOPEP-UWM
database, exist which allow prediction of the different peptides which
may be released using specific food protein substrates and hydrolytic
enzymes. For example, yak milk casein was identified as a potential
precursor for the release of potent angiotensin converting enzyme
(ACE) inhibitory peptides using BIOPEP-UWM database analysis (Lin
et al., 2018a, 2018b). Subsequently, the ‘Enzyme(s) action’ tool in
BIOPEP-UWM was used for the in silico proteolysis of yak milk caseins.
The outcome from this work was the discovery of three novel ACE in-
hibitory peptides, i.e., PFPGPIPN, KYIPIQ and LPLPLL derived from yak
milk casein. Bioinformatics-driven approaches were also employed in
the discovery of novel BAPs derived from bovine milk proteins. For
instance, Norris, Poyarkov, O’Keeffe, and FitzGerald (2014) used a
targeted approach to generate novel ACE inhibitory peptides from bo-
vine β-casein. Hydrolysis of this P rich substrate with a P specific en-
zyme, prolyl endoproteinase (An-PEP) from Aspergillus niger, led to the
release of peptides containing C-terminal P residues. Among the iden-
tified peptides released, FLQP had the most potent ACE inhibitory ac-
tivity with an inhibitory concentration mediating 50% inhibition of
activity (IC50) value of 68.7 μM.
While there are many advantages in the use of in silico approaches in
the targeted release of BAPs from milk protein substrates there are still
a number of limitations to the widespread usage of this technique for
BAP generation. For example, different strategies have been employed
to rank protein substrates with respect to their ability to act as potent
sources of BAPs. However, some potency indices/predictors do not take
into account overlapping sequences within specific regions of protein
molecules and thereby may overestimate the bioactive potency of a
particular protein molecule (Nongonierma & FitzGerald, 2017). There
are also limitations in the use of enzyme cutters for prediction of the
release of peptides from specific milk protein molecules. The currently
available online enzyme cutters are restricted to a limited number of
hydrolytic activities and it is conceivable that the release of specific
peptide sequences from a milk protein molecule would require an en-
zyme with a specificity not included in existing online enzyme cutters.
Furthermore, enzyme cutters do not take into account operational
parameters such as, the influence of pH, substrate total solids, incuba-
tion temperature and duration of incubation and ionic/salt effects on
enzyme activity (Cheison & Kulozik, 2017; Nongonierma & FitzGerald,
2016b). It was demonstrated, for e.g., that the incubation temperature
(i.e., 37 vs 50 °C) employed led to differences in the peptides released
during the hydrolysis of bovine β-casein with glutamyl endopeptidase
(Kalyankar, Zhu, O’ Keeffe, O’ Cuinn, & FitzGerald, 2013). Therefore,
these limitations need to be considered when selecting substrates and
hydrolytic enzymes for the targeted release of BAPs from milk protein
substrates.
3. Milk protein-derived bioactive peptide discovery using QSAR
QSAR is an approach which can be employed to determine the re-
lationship between the sequence/structure of a compound and its bio-
logical activity (Kubinyi, 1997). QSAR has been widely utilised for the
optimal generation and development of non-toxic synthetic drugs in the
pharmaceutical industry. However, in recent years its application has
been implemented in the discovery of food protein derived BAPs (for
reviews see: Iwaniak, Minkiewicz, Darewicz, Protasiewicz, and Mogut
(2015); Nongonierma and FitzGerald (2016a)). The structure of pep-
tides having different bioactivities have been studied using QSAR
models, e.g., peptides with ACE inhibitory activity (Jing et al., 2014;
Lin et al., 2018a, 2018b; Lin, Zhang, Han, & Cheng, 2017; Majumder &
Wu, 2010; Pripp, Isaksson, Stepaniak, & Sørhaug, 2004; Sagardia, Roa-
Ureta, & Bald, 2013; Tripaldi et al., 2018; Vukic et al., 2017; Wu, Aluko,
& Nakai, 2006a, 2006b), renin inhibitory activity (Udenigwe, Li, &
Aluko, 2012), antioxidant activity (Chen, Chen, Yao, & Li, 2018; Li & Li,
2013; Li, Li, He, & Qian, 2011; Matsui et al., 2018; Tian et al., 2015),
antimicrobial activity (Jenssen, 2011) and DPP-IV inhibitory activity
(Nongonierma & FitzGerald, 2016c).
Generally, the QSAR approach involves a series of steps which are
summarized in Fig. 2. The first step involves the collection of data in
order to build a complete library of peptides for subsequent analysis of
their structure activity interactions. These data can be obtained from
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the literature as well as from different protein and peptide databases
which are available online, e.g., BIOPEP-UWM, MDpep, Uniprot. These
databases generally contain details of BAP structures including amino
acid sequence and hydrophobicity as well as bioactivity (e.g., ACE or
DPP-IV inhibitors, antioxidants, antimicrobials). A dataset of peptides
with specific structural and biological features is then selected for fur-
ther study. Another feature used in QSAR studies is the minimum
analogue peptide set (MAPS) approach in which a minimum number of
analogue peptides with varied structural features are included in the
QSAR model (Hellberg et al., 1991; Nongonierma, Dellafiora, et al.,
2018). Once the dataset is generated, the second step is to classify the
peptides based on specific molecular descriptors of their different
structural features (Li et al., 2011; Lin et al., 2017; Pripp, 2006;
Sagardia et al., 2013; Wu, Aluko, & Nakai, 2006a). This step consists in
the selection of various molecular properties or amino acid descriptors.
These are divided into different levels based on structure, i.e., from 1D
to 4D, where 1D represents the primary sequence, 2D refers to the
secondary structure, 3D corresponds to the tertiary structure or the
conformational shape of the peptide and 4D relates to multiple con-
formations (quaternary structure). The so-called 3z, 5z- and v- scale
descriptors are the most utilised in QSAR studies. These descriptors
represent the hydrophilicity, size, charge and physicochemical prop-
erties such as steric and electronic properties, van der Waals interac-
tions and net charge index (Nongonierma & FitzGerald, 2016a). Other
descriptors which have been recently introduced have been reviewed in
Danishuddin and Khan (2016). Once each peptide has been described
with its corresponding descriptors, a specific number of peptides may in
some instances be excluded from the dataset for use in validation of the
model. Analysis of the dataset by QSAR modelling involves the utili-
sation of mathematical equations and computational models, e.g.,
multiple linear regression (MLR), partial least square regression (PLSR),
principal component analysis (PCA) and artificial neural networks
(ANN) (Dziuba & Dziuba, 2014; Fukunishi et al., 2017; He et al., 2012;
Yin, 2012). The model is initially applied to known peptide sequences
and then validated with those peptides that had been excluded from the
training list. Finally, confirmatory studies are performed in order to
verify the predicted versus the experimental results. In this case, pep-
tides with the highest predicted bioactivities, as determined in silico by
the QSAR model, are synthetised and analysed in vitro or in vivo for their
bioactive properties to determine the accuracy of the model (Tong, Li,
Li, & Bai, 2017).
A number of studies have reported on BAPs predicted by QSAR to be
highly bioactive. Some of these peptides can be found in different food
sources, e.g., milk, meat, egg and plants (Gu, Majumder, & Wu, 2011;
Lin et al., 2017; Majumder & Wu, 2010). To date, milk derived peptides
are the substrates most studied (Table 1). In general, the majority of the
QSAR studies on BAPs from milk protein have been performed to
identify ACE inhibitors (Kumar et al., 2015; Nongonierma & FitzGerald,
2016a). These peptides are usually characterised by their short se-
quence (di-and tripeptides) with P at the C-terminus or the presence of
hydrophobic bulky amino acids at the C-and N-termini (Nongonierma &
FitzGerald, 2016a, 2016b). QSAR analysis was performed on peptides
(containing at least 5 amino acid residues) from ovine and bovine
casein. It was reported that the presence of a P residue at the C-terminus
was important for ACE inhibitory activity. Several peptides were pre-
dicted to have ACE inhibitory activity, e.g., LHLPLP, LLYQEPVLGP,
LYQEPVLGP, YQEPVLGP, FTGPIPN, LSQPK, VRGPFPI and VMFPPQS
from β-casein, FVVAPFPE, VVAPFPE VAPFPEVF, APFPEVF and VAPF-
PEVFG from αs1-casein, YQGPIVLNPW, YPVEPF, and YQKFPQY from
αs2-casein and FLPYPY from κ-casein (Bounouala, Roudj, Karam, Recio,
& Miralles, 2017). A QSAR study on milk BAPs reported a correlation
between hydrophobicity and positively charged amino acids in the C-
terminal position and potent ACE inhibitory activity. However, when
peptides had more than six amino acid residues the correlation de-
creased emphasising the importance of steric properties on ACE in-
hibitory activity (Pripp et al., 2004; Pripp, 2005). The above features
have been studied by QSAR analysis for di- and tripeptides (Wu, Aluko,
& Nakai, 2006b) as well as for peptides with more than 4 amino acids
(Wu et al., 2006a). QSAR studies were also used to predict the ACE
inhibitory activity of yak milk casein-derived peptides (Lin et al., 2017).
The authors used a large database consisting of 127 penta-, 131 hexa-,
57 hepta- and 49 octapeptides based on previous studies, and a 5 z-scale
amino acid descriptor was employed (involving lipophilicity, steric
properties, electronegativity, electrophilicity and hardness). The amino
acid descriptors were analysed using PLSR. The overall outcome for
penta-, hexa- and heptapeptides was that the amino acid at the C1
position was key for ACE inhibitory activity whereas for octapeptides it
was the amino acid located at the C3 position. In conjunction with
molecular docking, it was predicted that PFPGPIPN, KTIPTQ, LPLPLL
obtained from hydrolysis of casein with proteinase K, trypsin and pa-
pain, respectively, were potent ACE inhibitory peptides. Subsequent
confirmatory studies showed that the predicted IC50 values were rela-
tively similar to the experimentally determined values (ACE IC50 values
of 12.79 vs 4.91, 7.28 vs 5.33 and 10.46 vs 9.11 μM for in vitro and in
silico of PFPGPIPN, KTIPTQ, LPLPLL, respectively) (Lin et al., 2017).
Based on that study and using the same QSAR model for ACE inhibition,
the authors identified 16 additional peptides from yak milk casein,
where KFPQY showed the most potent ACE inhibitory activity
(IC50= 12.37 ± 0.43 μM) (Lin et al., 2018a, 2018b). Jing et al. (2014)
developed a QSAR model in an attempt to identify tripeptides from
bovine milk with in vivo antihypertensive activity. The model was
generated using the sequences of 17 published anti-hypertensive
Fig. 2. Schematic representation of the sequential steps involved in quantita-
tive structure–activity relationship (QSAR) modelling for the identification of
bioactive peptides.
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peptides derived from bovine and human milk and was further applied
to 27 tripeptides found in bovine milk protein sequences. The QSAR
model was constructed using a three z-scale approach including lipo-
philicity, steric properties or side chain bulk/molecular size and elec-
tronic properties for each amino acid. Confirmatory studies with syn-
thetic peptides showed that IPP, VIP and IVP had ACE IC50 values of
7.6, 26.1 and 49.7 µM, respectively, confirming the validity of the
model generated. Additionally, IPP, VIP and IVP had an hypotensive
effect in spontaneously hypertensive rats by lowering systolic blood
pressure by 17, 12 and 24%, respectively (compared to the control
group) (Jing et al., 2014). LQYPYQGPIVL (from αs2-casein), PEIMG-
VPK and FPPQSVL (from β-casein) were predicted by QSAR to be highly
potent ACE inhibitory peptides which were released during in vitro
gastrointestinal digestion of fermented goat milk (Moreno-Montoro
et al., 2018). Another QSAR study predicted that lactoferrin had en-
crypted within its sequences some of the most potent ACE inhibitory
peptides of all the milk proteins. The study highlighted VRW with a
predicted ACE IC50 value of 0.6 μM and related this activity to lacto-
ferrin sequences being rich in hydrophobic and positively charged
amino acids (Gu et al., 2011). Vukic et al. (2017) recently reported the
identification of di- and tripeptides with ACE inhibitory activity from
milk using a combination of 3D-QSAR and molecular docking. The
principles of 3D-QSAR are similar to those of the classic QSAR but in-
clude the 3D geometric structures of the peptides. Due to the additional
complexity, the analysis was performed using the comparative mole-
cular field analysis (CoMFA) method (model of steric and electrostatic
interactions) (Cramer, Patterson, & Bunce, 1988). The results for di-
peptides showed that W at the C-terminus had the highest predicted
ACE IC50 values due to favourable steric interactions. Electronegativity
was also found to be favourable for ACE inhibition. On the other hand,
dipeptides containing G, A and L had the lowest ACE inhibitory acti-
vity. In tripeptides, steric interactions were associated with the N-
terminal residues. The highest ACE inhibitory activity was predicted for
KP, however, no confirmatory studies were performed (Vukic et al.,
2017).
The antioxidant activity of tripeptides from β-lactoglobulin was
studied using QSAR analysis reporting that antioxidant activity was
dependent on the electronic and hydrogen-bonding properties of the
amino acids. The study discovered that the steric properties of the
amino acid residues at the C- and N-termini played an important role in
antioxidant activity (Li et al., 2011; Tian et al., 2015). Due to the
complexity and the different mechanisms of action of antioxidant
peptides, Li and Li (2013) applied QSAR modelling to peptides from
different sources, including human milk, and subsequently, determined
the antioxidant activity using different assays. The authors reported
that the importance of specific amino acids to antioxidant activity was
antioxidant assay dependent. It was reported that the amino acid at
C2 was important for Trolox equivalent antioxidant capacity (TEAC), at
C3 for oxygen radical antioxidant capacity (ORAC), at C4 for superoxide
radical (SOR) and the presence of hydrophobic amino acids with low
electronic or steric/hydrogen bonding properties, e.g., W, Y, M, L, T,
and F were favourable for antioxidant activity. On the other hand,
hydrogen bonding was not relevant for all antioxidant assays (Li & Li,
2013).
Milk derived peptides (> 250) were studied using a QSAR approach
to identify the structural features of DPP-IV inhibitory peptides. The
main observed characteristic of potent DPP-IV inhibitors was the pre-
sence of an I residue in position N1 and a P in the N2 position. On the
basis of these features, IPM and LPVPQ were identified with DPP-IV
IC50 values of 69.5 ± 8.7 and 43.8 ± 8.8 μM, respectively
(Nongonierma & FitzGerald, 2016c). A similar approach was used to
predict the sequences of peptides from camel milk resulting in the
identification of LPVP and MPVQA with DPP-IV IC50 values of 87.0 and
93.3 µM, respectively (Nongonierma, Paolella, Mudgil, Maqsood, &
FitzGerald, 2018). A QSAR model was applied in order to study the
structural characteristics of IPI (the most potent DPP-IV inhibitor;
IC50= 3.6 µM). A MAPS approach was used in order to minimise the
number of peptides in the dataset to 33. The results of the model along
with docking studies determined that the hydrophobicity of the amino
acids located at the N-terminal and close to the C-terminal positions
was an important feature for DPP-IV inhibitory peptides. In particular,
the location of P at position 2 in tripeptides (e.g., VPP from milk pro-
tein) was important for DPP-IV inhibitory potency (Nongonierma,
Dellafiora, et al., 2018).
QSAR has also been used in the study of milk protein derived an-
timicrobial peptides (Jenssen, 2011). These studies identified analogs
for the antimicrobial peptide lactoferricin from the minor whey protein
lactoferrin. The key factor was reported to be the propensity for an
helical structure and a cationic charge in the amino acids at positions
C4-9 (Nakai, Chan, Li-Chan, Dou, & Ogawa, 2003). QSAR modelling
and ANN approaches have been also used to determine the organoleptic
properties (such as peptide bitterness (Murray et al., 2018)) as well as
the toxicity (ToxinPred; http://crdd.osdd.net/raghava/toxinpred/) and
allergenicity (AlgPred; http://crdd.osdd.net/raghava/algpred/) of
peptides (Tu et al., 2018).
It is evident therefore that QSAR modelling may be a good strategy
for BAP identification. However, some limitations have been observed
when following this approach (Cherkasov et al., 2014). A critical point
for the efficiency of QSAR studies is the selection of the correct amino
acid descriptors. Although different scales have been developed, the
descriptors may be insufficient to correlate certain peptide character-
istics with specific bioactivities (e.g., hydrophobicity and antioxidant
activity) or in certain cases when descriptors have been used in com-
bination essentially describing the same information twice. Further-
more, some studies utilise datasets with low numbers of peptides which
are not representative and consequently result in low correlations be-
tween predicted and experimental values (Cherkasov et al., 2014). The
use of negative datasets, i.e., including peptides with no specific activity
is also recommended in order to challenge the model. Another limita-
tion in the use of QSAR is the lack of knowledge on the mechanism of
action of certain bioactivity properties (e.g., antioxidant activity) as
well as the mode of action of enzyme inhibitory peptides which can act
as competitive or non-competitive inhibitors. Therefore, there is always
a need for confirmatory studies performed either in vitro or in vivo
(Fig. 2). Despite these limitations, it is evident that QSAR in combina-
tion with other in silico strategies (e.g., molecular docking), has been
successfully used in the prediction and identification of milk protein
derived BAPs.
4. Docking of milk protein derived BAPs
The knowledge of molecular structure achieved by employing sev-
eral advanced techniques such as circular dichroism (CD), fourier
transform infrared (FTIR), X-ray crystallography, nuclear magnetic re-
sonance (NMR) spectroscopy, etc., together with molecular docking are
the basis for the discovery of a range of molecules with specific biolo-
gical activities. Molecular docking is an important in silico technique
which is employed during the discovery of biological molecules (Yuriev
& Ramsland, 2013; Yuriev, Holien, & Ramsland, 2015). This technique
is used to predict the preferential orientation between a receptor (target
molecule after removal of co-crystalized ligand prior to modeling) and a
ligand. In addition, this technique is employed to elucidate the mode
and the energy of the binding interaction (Khalesi et al., 2016; Mukesh
& Rakesh, 2011; Taylor, Jewsbury, & Essex, 2002).
By using molecular docking the possible interactions between the
target molecule (e.g., enzyme) and a specific ligand (e.g., BAPs) is
screened (Tu et al., 2018). The key concept of molecular docking is to
develop an appropriate solution to elucidate the minimum free energy
(ΔG) of interaction per mole of ligand (Pagadala, Syed, & Tuszynski,
2017). Several software packages such as AutoDock vina, DOT, GOLD,
GRIDock, HEX, ICM and Tag-Dockare are available for the performance
of molecular docking (Pagadala et al., 2017) (Table 2).
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Recent studies on milk protein and peptide docking have focused on
three main categories: (1) study of the possibility of BAPs released
during milk protein digestion to activate or inhibit specific enzymes; (2)
study of the potential of milk proteins, including caseins and whey
proteins, as carriers for drugs and health enhancing components; and
(3) study of the interaction between milk proteins with other food
components (e.g., phenolic compounds) in blended products.
Molecular docking has been proposed as an approach for the better
understanding of the possibility of BAPs possessing ACE and DPP-IV
inhibitory activity along with antioxidant and anti-thrombotic activity.
The application of molecular docking for the discovery of peptides
originating from a specific substrate (e.g., milk proteins) offers the
possibility for high throughput in silico screening of large amounts of
peptides for a specific biofunctional property. The approach can result
in reduced cost and more rapid results due to being less laborious
compared to conventional laboratory-based screening. However, con-
firmatory experimental studies with a small number of the highly
ranked peptides are always necessary. Table 3 provides details of some
recent docking studies regarding the interaction of milk protein derived
BAPs with target enzymes.
Tu et al. (2017) for example, performed molecular docking for the
identification of anti-thrombotic activity associated with peptides in a
tryptic digest of casein. Thrombin is a key serine endopeptidase with
functions involving a number of cleavage reactions which are essential
for clot promotion/inhibition in hemostasis (Crawley, Zanardelli,
Chion, & Lane, 2007). Docking of possible interaction between the
peptides released by a serine proteinase and thrombin showed that 60%
of the peptides could interact with thrombin via hydrogen bonding.
One peptide from β-casein consisting of FQSEEQQQTEDELQDK, was
predicted to be highly specific for binding with thrombin and to possess
thrombin inhibitory activity. Interactions between the peptide and K36-
Q38-R73-T74-K81-I82-K110 of thrombin were predicted during mole-
cular docking. Furthermore, the in silico prediction in respect to potent
thrombin inhibitory activity was subsequently confirmed experimen-
tally (Tu et al., 2017).
The possibility of employing eight peptides released during
enzymatic digestion of goat milk αs2-casein to activate glucokinase
(GCK) was evaluated using in silico docking (Fatchiyah, Rahasta, &
Cairns, 2017). GCK regulates the conversion of glucose to glycogen in
the liver and is therefore involved in hepatic glucose production
(Matschinsky, 2009). The study predicted the ability of specific pep-
tides to induce binding between GCK and glucose (Fatchiyah et al.,
2017). The docking and visualization results showed that NMAIHPR
and TNAIPYVR from αs2-casein were capable of binding to the active
site of GCK, thus potentially activating the enzyme. The main interac-
tions between the peptides and GCK consisted of hydrogen bonding and
electrostatic interactions (Fatchiyah et al., 2017).
The ability of peptides to interact with advanced glycation end
product (AGE) receptors (RAGE), which is associated with numerous
diseases, e.g., cardiovascular disease, advanced renal disease and in-
flammation, was also assessed (Fatchiyah et al., 2015; Nowotny,
Schroter, Schreiner, & Grune, 2018). Avoiding the interaction between
AGE-RAGE has potential health enhancing consequences. Molecular
docking showed that NMAIHPR, KISQYYQK and TNAIPYVR from αs2-
casein were able to block the C-domain bond of RAGE and compete
with AGE, thus partially inhibiting AGE-RAGE binding. The binding
energies for all three peptides to RAGE were in the range of −350 to
−380 kJ/mol, comparable with those of argypirimidine (−378.35 kJ/
mol), imidazole (−74.57 kJ/mol), pentosidine (−301.25 kJ/mol) and
pyrraline (−400.72 kJ/mol), indicating that the affinity of RAGE to
interact with these peptides was high.
Docking of di- and tripeptides to the active site of ACE has been
reported in a number of studies (Norris, Casey, FitzGerald, Shields, &
Mooney, 2012; Pripp, 2007; Yu, Chen, et al., 2018; Yu, Zhang, et al.,
2018; Zhang et al., 2018). Recently, the main type of interactions be-
tween peptides with high ACE inhibitory activity and ACE was found to
be hydrophobic in nature (Vukic et al., 2017). Among the dipeptides,
VW and KW were shown to be the most potent inhibitors of ACE. In
both cases, W was positioned deep in the hydrophobic pocket of ACE.
Hydrogen bonding and electrostatic interaction were also observed
with these dipeptides. The peptides with the lowest ACE inhibitory
activity were observed to lack hydrophobic amino acid residues. The
presence of an I residue, as an apolar residue, did not yield high ACE
inhibitory activity, possibly due to the short chain length of this amino
acid. Among the tripeptides, MKP and IVY have been shown to possess
maximum ACE inhibitory activity, which is most likely due to their high
hydrophobicity. The presence P and Y within tripeptides was associated
with being located deep within the hydrophobic pocket of ACE. Other
tripeptides with significant ACE inhibitory activity were also shown to
contain P residues. These results are similar to the findings of Panyayai
et al. (2018), who reported that W and other hydrophobic amino acids
play a major role in ACE inhibition. These findings arise from a com-
putational study examining 8000 potent ACE inhibitory tripeptides
released from food proteins.
DPP-IV is a serine exopeptidase which can cleave incretin hormones
such as glucagon-like peptide-1 and glucose-dependent insulinotropic
polypeptide, resulting in a loss of their insulinotropic activity. DPP-IV
inhibitors are used as antihyperglycaemic agents for the better regula-
tion of type 2 diabetes (Bihan, Ng, Magliano, & Shaw, 2016). Maximum
inhibition of DPP-IV by tripeptides was observed with sequences having
Table 2
Examples of different molecular docking software resources employed for the in

















Summary of representative recent molecular docking studies on the interactions of milk protein derived bioactive peptides.
Milk protein source Bioactivity Sequences Software Reference
Various milk peptides Antimicrobial activity TKLTEEEKNRLNFLKKISQRYQKFALPQYLK The web server RaptorX 2011 coupled by PyMOL (Liu et al ., 2015)
Goat αs2-casein RAGE inhibition NMAIHPR, KISQYYQK and TNAIPYVR Ligplot+ coupled by PyMOL (Fatchiyah et al., 2015)
Bovine β-casein Thrombin inhibition FQSEEQQQTEDELQDK Discovery Studio (Tu et al., 2017)
Goat αs2-casein GCK activation NMAIHPR and TNAIPYVR Ligplot+ coupled by PyMOL (Fatchiyah et al., 2017)
Various milk peptides ACE inhibition VW and KW, MKP and IVY Surflex-Dock coupled by PyMOL (Vukic et al., 2017)
Various milk peptides DPP-IV inhibition IPI GOLD coupled by HINT (Nongonierma et al., 2018)
RAGE: Advanced glycation end product receptors; GCK: glucokinase; ACE: angiotensin converting enzyme; DPP-IV: dipeptidyl peptidase IV.
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P at position 2 (Nongonierma, Dellafiora, et al., 2018). Modeling the
interaction between several highly potent DPP-IV inhibitory tripeptides
showed a limited correlation between the software predicted ranking
score and experimentally determined DPP-IV inhibition. These results
indicated that the free energy was not directly associated with the DPP-
IV inhibitory activity. It was also shown that non-competitive DPP-IV
inhibitory peptides should not be employed for docking analysis, since
many tripeptides having N-terminal W are strong inhibitors of DPP-IV,
even though they do not display a competitive mode of inhibition.
Moreover, it was shown that peptides having P and W together may
inhibit the enzyme with a mixed mode of inhibition. Therefore, it is
important to have knowledge of the mode of peptide action when
performing docking studies between peptides and enzymes
(Nongonierma, Dellafiora, et al., 2018).
In a docking study on antimicrobial peptides, Liu, Eichler, and
Pischetsrieder (2015) identified 23 peptides (18 from αS1-casein, 4 from
αS2-casein and 1 from β-casein) from a possible 248 peptides with an
antimicrobial effect, based on their hydrophobic amino acid content.
The subsequent experimental confirmatory study demonstrated the
bacteriostatic activity of 14 peptides. The most potent antimicrobial
fragment visualized by PyMOL was reported to be TKLTEEEKNRLNF-
LKKISQRYQKFALPQYLK from αS2-casein.
The results obtained from computational docking are sometimes
difficult to comprehend when compared with actual experimental re-
sults (Bonvin, 2006; Yuriev, Agostino, & Ramsland, 2011). This is due
to the fact that there are a number of limitations to molecular docking
of peptides. These include difficulties in: (1) identifying the correct
algorithms; (2) properly accounting for molecular flexibility and con-
formational changes; (3) the requirement to work with peptides having
the same interaction mechanisms with enzyme/receptors; (4) limitation
of simulating real conditions including temperature, pH and con-
centration; (5) instability of peptides in real systems; (6) variable
quality crystal structures and alignment of the molecular structures; (7)
the nature of protein source; and (8) the need to disregard peptides
having mixed type enzyme inhibitory interactions.
5. Milk protein–derived bioactive peptide yield optimisation
using DOE and RSM
Multifactorial DOE is an in silico technique which can be applied
when studying the influence of a series of parameters on a specific
output of interest with the aim of optimising a particular process
(Knowles, 2011). In dairy protein/peptide research, DOE has been
employed, e.g., to optimise the release of peptides with biological ac-
tivity (Cermeño et al., 2019; Contreras, Hernández-Ledesma, Amigo,
Martín-Álvarez, & Recio, 2011; Nongonierma & FitzGerald, 2018;
Nongonierma et al., 2019; Nongonierma, Maux, Esteveny, & FitzGerald,
2017; Nongonierma, Mazzocchi, Paolella, & FitzGerald, 2017;
Nongonierma, Paolella, et al., 2018; van der Ven, Gruppen, de Bont, &
Voragen, 2002) and to help reduce protein antigenicity/allergenicity
(Liu, Luo, & Li, 2012; Nitride et al., 2019; Zheng, Shen, Bu, & Luo,
2008). All DOE protocols follow the same basic approach (Fig. 3).
Firstly, it is necessary to clarify the objective(s) to be achieved from a
given experiment and the scope of the investigation. Secondly, it is
necessary to define the output to be optimised, e.g., a biological output
such as antioxidant and DPP-IV or ACE inhibitory activity. Thirdly, it is
necessary to choose factors or parameters that can influence the output
of interest, i.e., if it is an enzyme catalysed reaction this can involve a
variation in different experimental parameters such as incubation
temperature, incubation time, enzyme:substrate (E:S), pH and total
solids concentration. In this regard, it is necessary to change the ex-
perimental parameters at least once to observe the difference it may
contribute to the output of interest. Fourthly, it is necessary to select the
experimental design taking into account the boundaries of the study,
i.e., in an enzymatic reaction this includes the pH or temperature range
in which the enzyme is active. This will indicate the number of factors
and levels, and resources required to carry out the appropriate ex-
periments (Knowles, 2011). DOE allows a reduction in the overall
number of experiments to be performed to the minimum while allowing
the obtention of the maximum extent of information. Once the DOE has
been developed, it is necessary to perform the experiment(s) to obtain
actual data which when analysed will allow the development of a
mathematical model using, e.g., MLR analysis. This model will inform if
it is possible to link the effect of the parameters which have been varied
to the output of interest. Usually at this stage, RSM analysis may/will
allow prediction of the optimal conditions required in order to max-
imise the output of interest. RSM is a collection of mathematical and
statistical techniques based on the fit of a polynomial equation to the
experimental data. RSM analysis describes the behavior of a data set
with the objective of making statistical predictions (Bezerra, Santelli,
Oliveira, Villar, & Escaleira, 2008). Table 4 shows different software
programs used to carry out DOE and RSM. The predicted optimal
conditions are then employed in actual experiments to validate the
model developed. A number of reports have reviewed the use of DOE
and RSM in food protein hydrolysis (Nongonierma & FitzGerald, 2016b,
2018).
Publications, in the last 5 years, in relation to the use of DOE in the
targeted release of milk protein-derived BAPs are summarised in
Table 5. As can be observed, DOE have been used to optimise hydrolysis
conditions for composite milk proteins, their fractions (casein, whey
proteins) and individual proteins (α-lactalbumin). Optimisation of the
release of the milk protein-derived DPP-IV inhibitory peptide, IPI, and
mineral binding casein phosphopeptides have been studied using DOE.
It is possible to divide these reports on the basis on whether they focus
on enzymatic hydrolysis, fermentation or binding interations (Table 5).
DOE has been extensively employed in optimisation of the
Fig. 3. Schematic representation of the sequential steps involved in the appli-
cation of design of experiments (DOE) and response surface methodology
(RSM) for optimisation of the production of bioactive peptides.
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enzymatic hydrolysis processes for different bioactivity outcomes. This
is particularly the case during optimisation of the hydrolysis of milk
proteins to release antioxidant and DPP-IV inhibitory activity peptides
(Table 5). DOE has been employed, for example, in optimising the re-
lease of antioxidant activity during the hydrolysis of whey proteins with
Alcalase® (Athira et al., 2015) and during the hydrolysis of caseins with
Protamex™ (Nongonierma, Maux, et al., 2017). Both studies consisted
of a 3-factor 3-level design by modifying pH, temperature and time of
hydrolysis while keeping the E:S constant. The models obtained de-
monstrated a significant effect of temperature, pH and time on anti-
oxidant activity release in the case of whey protein hydrolysis with
Alcalase® (Athira et al., 2015) whereas only hydrolysis time was sig-
nificant in the case of casein hydrolysis with ProtamexTM
(Nongonierma, Maux, et al., 2017). In both cases, the models were
subsequently validated experimentally.
The literature in relation to enzymatic hydrolysis for optimisation of
DPP-IV inhibitory activity during milk protein hydrolysis has generally
incorporated factors such as: temperature, E:S ratio, hydrolysis time
and pH and use a 3 factor 3 level design. The boundaries of the ex-
perimental design were usually based on the optimum conditions of the
enzyme as determined in previous experiments. Milk protein isolate
(MPI) derived peptides with DPP-IV inhibitory activity were generated
with trypsin (Nongonierma, Mazzocchi, et al., 2017) and Neutrase
0.8L™ (Nongonierma, Lalmahomed, Paolella, & FitzGerald, 2017) under
similar temperature, E:S and hydrolysis time conditions. The findings
showed differences in the relationships of the parameters that influence
DPP-IV inhibitory activity between the two enzymes indicating the
enzyme specificity dependence of the reaction. There was good agree-
ment between the model generated with trypsin and the obtained ex-
perimental hydrolysates, whereas there was an underestimation of the
DPP-IV IC50 value obtained experimentally for the hydrolysates gen-
erated with Neutrase 0.8L™. These differences between the predicted
optimum conditions and the experimental values may have been due to
other parameters not analysed in the DOE model such as total solids
content, the peptides produced during hydrolysis inhibiting the pro-
teolytic activity, to pH, to a limitation in the substrate or degradation of
the DPP-IV inhibitory peptides once released (Nongonierma,
Lalmahomed, et al., 2017). Skim milk from camel has also been studied
using DOE to optimise DPP-IV inhibitory activity for hydrolysates
produced on incubation with trypsin. In similarity with the above-
mentioned previous model in which MPI was hydrolysed with Neutrase
0.8L™, in the case of camel proteins, there was an underestimation of
the IC50 value of the hydrolysates obtained under the predicted opti-
mised conditions (Nongonierma, Paolella, Mudgil, Maqsood, &
FitzGerald, 2017). In the case of trypsin (PTN 6.0) hydrolysis of whey
proteins from camel milk, only the E:S showed a significant effect in the
model developed by DOE (Nongonierma et al., 2019). DOE has also
been employed during casein hydrolysis with Protamex™ to optimise
the antioxidant activity and DPP-IV inhibitory activity of the hydro-
lysates (Nongonierma, Maux, et al., 2017). The DOE consisting of 3
factors (temperature of reaction, pH and hydrolysis time) and 3 levels,
resulted in a set of 15 experiments. In this case, it was necessary to
develop two MLR models, one for each bioactivity tested, and it was
seen that the factors studied influenced bioactivity output in different
Table 4
Summary of some reports outlining the application of design of experiments and response surface methodology for optimisation of bioactive peptide release from
milk proteins.
Substrate Species Bioactivity Enzyme Parameters DOE Reference
Skim milk Bovine ACE inhibition Carboxypeptidase and
aminopeptidase released from
Kluyveromyces marxianus
Fermentation T (22–34), pH
(5.5–7), inoculum level (2–10%),
rotation speed (0–200 rpm)
4 factors
5 levels
Li et al. (2015)
Casein phosphopeptide Bovine iron binding Mass ratio Fe-CPP (0.04–0.16), pH
(5–7.5), holding time (40–80min)
3 factors
3 levels
Delshadian et al. (2018)
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T: temperature; E:S: enzyme to substrate ratio; ACE: angiotensin converting enzyme; DPP-IV: dipeptidyl peptidase IV.
Table 5
Some examples of programs employed to carry out design of experiments and response surface methodology (all web sites were verified in September 2019).
Software Website Reference
Design-Expert https://www.statease.com/software/design-expert/ Athira et al. (2015), Li et al. (2015), Delshadian et al. (2017)
Develve https://develve.net/ Open source
Matlab https://uk.mathworks.com/products/get-matlab.html Nongonierma et al. (2016; 2017, 2018, 2019)
Minitab https://www.minitab.com/en-us/ (Cermeño et al., 2019)
OpenMDAO https://openmdao.org/ Open source
PyDOE https://pythonhosted.org/pyDOE/ Open source
SAS https://www.sas.com/en_ie/home.html Zheng et al. (2008), Liu et al. (2012)
Statgraphics http://www.statgraphics.com/ Contreras et al. (2011), Tavares et al. (2011)
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ways (Nongonierma, Maux, et al., 2017).
DOE has also been employed for optimisation of the amino acid
residue position in peptides and assessment of its influence on DPP-IV
inhibitory activity together with other in silico techniques, i.e., mole-
cular docking and QSAR (see Sections 2 and 3) (Nongonierma,
Dellafiora, et al., 2018). Based on the data obtaining by QSAR model-
ling, a factorial design model was developed consisting of 3 factors (3
different positions within a tripeptide sequence) and 2 levels (low and
high hydrophobicity of the amino acid side chains) to help design tri-
peptide alternatives of the potent milk protein derived DPP-IV in-
hibitory tripeptide, IPI. The authors subsequently analysed the DPP-IV
inhibitory activity of 15 different tripeptide sequences. The model
generated from the experimental data was used to predict the structures
of 9 tripeptides with high DPP-IV inhibitory activity all containing P at
position 2 (Nongonierma, Dellafiora, et al., 2018). This DOE approach
helped contribute to understanding the mechanism of inhibition of
DPP-IV based on the experimental outputs with the alternative peptide
sequences.
In the case of fermentation, (Li, Sadiq, Liu, Chen, & He, 2015)
employed DOE and RSM to optimise the production of ACE inhibitory
peptides from skimmed milk during fermentation with Kluyveromices
marxianus. The authors designed an experiment consisting on 4 factors
and 5 levels: fermentation temperature (22–34 °C), level of inoculum
(2–10%), pH (5.5–7.0) and rotation speed (0–200 rpm), leading to a
total of 30 experiments. The optimum conditions producing a potent
ACE inhibitory fermentate were predicted to be incubation at 32 °C, at
pH 6.5, using an inoculum level of 6% and a rotation speed of 189 rpm.
Experimental validation of the model confirmed those conditions as the
optimum to produce potent ACE inhibitory fermentates (Li et al., 2015).
In the area of fortified foods with specific BAPs, Delshadian et al.
(2018) used DOE and RSM to optimise the production of casein phos-
phopeptides (CPPs) rich in iron. The DOE had 3 factors (mass ratio of
iron to CPPs, pH and holding time) at 3 levels each, giving a total of 20
experiments. The optimum conditions predicted to produce the highest
binding of CPPs and the ferrous ion were pH 6.5, mass ratio of 0.14 and
a holding time of 72min. The predicted value for iron binding did not
differ significantly from the experimentally determined value (i.e.,
68.66 vs 67.62mg/g), confirming the validity of the model and the
important role of pH in the solubility of both ferrous iron and CPPs
(Delshadian et al., 2018).
Therefore, the recent literature shows that DOE and RSM have been
used successfully in optimisation of the BAPs released. Furthermore,
these techniques have been employed to optimise the conditions for
iron binding by CPPs. Newer uses of DOE involve its application in
structure-function assessment of BAPs, i.e, for DPP-IV inhibitory tri-
peptides. Up to now, DOE and RSM appear to have been mainly em-
ployed for lab-scale process optimisation for BAP release. However, as
has been pointed by Dullius, Goettert, and de Souza (2018) in the case
of other in silico strategies, the challenges for DOE and RSM will be in
extrapolation to industrial scale for the optimisation of BAP production.
6. Conclusion
The conventional methods for BAP generation and discovery, while
slow and tedious, have led to the elucidation of a range of different
BAPs from food protein sources. However, advances in relation to in
silico approaches for protein substrate and hydrolytic enzyme identifi-
cation, and in QSAR, in molecular docking and in DOE display sig-
nificant potential in enhancing the efficiency of the generation and
discovery of BAPs from food proteins. While there are many limitations
associated with in silico approaches, including the extent and quality of
information within publicly available databases, these strategies can
play a significant future role in the process of BAP generation and
identification.
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